

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: November 1, 2017

Date and Time of Meeting: Thursday, December 7, 2017 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: North Nevada Location:
Silver State Health Insurance Exchange
2310 S. Carson Street, Suite 3A
Carson City, NV 89701

Place of Meeting: South Nevada Location:
Silver State Health Insurance Exchange
150 N. Stephanie Street, Suite 100
Henderson, NV 89074

Please check with staff to verify room location

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=e7c160bfb8cdc5e1705129744ebe4f8c9>

OR

www.webex.com, select “Join,” enter Meeting Number 319 354 044, your name and email and then select “Join.”

A Password should not be necessary, but if asked, enter, “q2TyYC56”

OR

*Nevada Department of Health and Human Services
Helping People -- It's Who We Are And What We Do*

Audio Only: (763) 957-6300

Event Number: 319 354 044

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Colleen McLachlan at: (775) 684-3722 or email cmclach@dncfp.nv.gov in advance, but no later than two working days prior to the meeting so that arrangements may be conveniently made.

AGENDA

1. Call to Order and Roll Call

2. Public Comment

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from September 28, 2017
- b. Status Update by the DHCFP
 - 1. Public Comment

4. Established Drug Classes Being Reviewed Due to the Release of New Drugs

- a. Gastrointestinal Agents – Functional Gastrointestinal Disorder Drugs
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Ophthalmic Agents – Ophthalmic Antihistamines
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action

- a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Respiratory Agents – Respiratory Anti-inflammatory Agents – Respiratory Corticosteroids
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Dermatological Agents – Topical Anti-inflammatory Agents – Immunomodulators: Topical
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Anti-infective Agents – Antivirals – Anti-Hepatitis Agents – Polymerase Inhibitors/Combination Products
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- f. Respiratory Agents – Respiratory Long-Acting Antimuscarinic/Long-Acting Beta-Agonist Combinations
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- g. Analgesics – Opiate Agonists – Abuse Deterrent
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

5. Established Drug Classes

- a. Dermatological Agents – Topical Analgesics
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- b. Biologic Response Modifiers – Immunomodulators – Targeted Immunomodulators
 1. Public Comment

2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - c. Approve exception to a trial of two preferred agent requirement.
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
6. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
7. **Closing Discussion**
- a. Public comments on any subject
 - b. Date and location of the next meeting
 - c. Adjournment

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfnv.gov/> and notice.nv.gov/.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcfnv.gov/>; Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Colleen McLachlan at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.